Studies oxaliplatin chemotherapy after surgery for gastrointestinal neuroendocrine carcinoma
Observes chemotherapy with oxaliplatin after surgery in adults with gastrointestinal neuroendocrine carcinoma.
Plain-language title generated from the registry record
Registry title: Oxaliplatin-Based Adjuvant Therapy for Gastrointestinal Neuroendocrine Carcinoma**
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07891572, who can take part
Where in China
- Peking Union Medical College HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT07891572
- Record updated
- 23 October 2026
- Original description
Patients with pathologically-confirmed gastrointestinal neuroendocrine carcinoma will be enrolled, to explore the efficacy and safety of oxaliplatin-based doublet chemotherapy in the adjuvant treatment of gastrointestinal neuroendocrine carcinoma. For patients after radical resection, adjuvant chemotherapy is recommended. XELOX, SOX or FOLFOX regimens can be selected based on the patient's physical status. Single-agent chemotherapy alone is not recommended.Read full original descriptionShow less
Efficacy and Safety of Oxaliplatin-Based Doublet Regimens as Adjuvant Therapy for Gastrointestinal Neuroendocrine Carcinoma
Patients with pathologically-confirmed gastrointestinal neuroendocrine carcinoma will be enrolled, to explore the efficacy and safety of oxaliplatin-based doublet chemotherapy in the adjuvant treatment of gastrointestinal neuroendocrine carcinoma. For patients after radical resection, adjuvant chemotherapy is recommended. XELOX, SOX or FOLFOX regimens can be selected based on the patient's physical status. Single-agent chemotherapy alone is not recommended.
Inclusion: Histopathologically-confirmed diagnosis of gastrointestinal neuroendocrine carcinoma; Patients with radical resection of tumour, unresectable locally-advanced disease or metastatic disease, regardless of tumour stage; No restriction on gender, aged between 18 and 75 years old; Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1. Hematological, hepatic and renal function parameters meet the criteria for chemotherapy administration; Expected survival time ≥ 3 months; Agree to undergo examinations, treatment and follow-up in accordance with this study protocol; agree to provide clinicopathological and follow-up data required for the study; and consent to the use of study-related data for subsequent research; Voluntarily participate in this clinical trial, understand the study procedures and be capable of signing the informed consent form.
Exclusion: Presence of another concurrent malignant tumour within 5 years prior to enrolment; Received any anti-tumour therapy within six months before enrolment; In the investigator's judgment, the patient has concomitant diseases (such as uncontrolled hypertension, severe diabetes, thyroid disorders, psychiatric diseases, etc.) or any other conditions that would seriously endanger patient safety or prevent completion of this study.